Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis Buys 4,259 Shares

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis acquired 4,259 shares of the stock in a transaction dated Tuesday, September 24th. The shares were acquired at an average cost of $4.70 per share, with a total value of $20,017.30. Following the completion of the transaction, the director now owns 41,767 shares in the company, valued at approximately $196,304.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rezolute Trading Up 5.5 %

Rezolute stock opened at $4.95 on Thursday. Rezolute, Inc. has a twelve month low of $0.72 and a twelve month high of $6.10. The stock has a 50 day moving average of $4.62 and a two-hundred day moving average of $3.78. The stock has a market capitalization of $274.08 million, a price-to-earnings ratio of -4.34 and a beta of 1.18.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). Equities analysts predict that Rezolute, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Guggenheim assumed coverage on Rezolute in a research report on Tuesday, August 27th. They set a “buy” rating and a $11.00 price objective for the company. Maxim Group upped their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a research report on Friday, September 20th. Craig Hallum initiated coverage on Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research report on Monday, September 9th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $11.57.

Institutional Trading of Rezolute

Hedge funds have recently added to or reduced their stakes in the stock. Jeppson Wealth Management LLC acquired a new stake in Rezolute during the 2nd quarter worth approximately $45,000. Virtu Financial LLC purchased a new position in shares of Rezolute during the 1st quarter worth approximately $37,000. XTX Topco Ltd raised its stake in shares of Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after buying an additional 22,660 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after buying an additional 42,597 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Rezolute during the 2nd quarter worth approximately $255,000. 82.97% of the stock is owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.